Código QR (código de barras bidimensional)

ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone   (ELd)   for relapsed/refractory  multiple myeloma (MM) based on the findings of the phase III randomized trial  ELOQUENT-2 (NCT01239797). Four-yea...

ver descrição completa

Na minha lista:
Principais autores: Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko
Formato: Artigo
Idioma:Inglês
Publicado em: PAGEPress Publications 2018-02-01
coleção:Mediterranean Journal of Hematology and Infectious Diseases
Assuntos:
Elotuzumab
multiple myeloma
SLAMF7
SLAM-associated protein (SAP)
EAT-2
Acesso em linha:https://www.mjhid.org/index.php/mjhid/article/view/3270
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados